Merck (NYSE:MRK) has finalized its takeover of privately held Themis, a Vienna, Austria-based developer of vaccines and immunomodulation therapies for infectious diseases, including COVID-19, announced last month.
Clinical trials testing a SARS-CoV-2 vaccine candidate should launch later this year.
https://seekingalpha.com/news/3584503-merck-completes-themis-buy-coronavirus-vaccine-trials-on-tap
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.